Physician profile
Mariah T Moore
NPI 1851954390
$1,803.89
in general payments reported to CMS, 2019-2025
21 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $144 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Travel and Lodging: $5.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.05 |
| Travel and Lodging | $5.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.27 | 2025 | |
| Edwards Lifesciences Corporation | $209.43 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $188.17 | 2025 | |
| Lilly USA, LLC | $181.39 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $167.49 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.19 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $135.78 | 2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $84.56 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $55.44 | 2024-2025 | Rexulti |
| Amgen INC. | $48.79 | 2024-2025 | Evenity, Otezla, Repatha |
| Axsome Therapeutics, INC. | $47.23 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.19 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $38.93 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Verona Pharma, INC. | $33.33 | 2025 | Ohtuvayre |
| Dynavax Technologies Corporation | $32.67 | 2025 | Heplisav-B |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.01 | 2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $28.60 | 2025 | |
| Vanda Pharmaceuticals INC. | $24.80 | 2024 | Hetlioz, Fanapt |
| Lundbeck LLC | $22.89 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.42 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $15.31 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.